Inclusion of cancer drug in WHO Covid Solidarity trial: CDSCO panel asks ICMR to submit more clarification
New Delhi: The expert panel of the Central Drugs Standard Control Organisation (CDSCO) has recently asked the apex medical research body, Indian Council of Medical Research (ICMR) to furnish more clarification for the inclusion of cancer drug Acalabrutinib, as part of the World Health Organization's global 'Solidarity' trial, which is testing drugs to find an effective treatment for Covid-19.
The recommendation came after ICMR's National AIDS Research Institute (NARI) submitted before the Subject Expert Committee (SEC) with a proposal for amendment in the protocol, including the addition of one new arm of Acalbrutinib in the Solidarity trial.
Acalabrutinib is a cancer drug developed by British pharmaceutical giant AstraZeneca and is branded as Calquence. The drug belongs to a class of medications called Bruton's tyrosine kinase (BTK) inhibitor, which blocks the action of the abnormal protein that signals cancer cells to multiply, stopping the growth of cancer cells.
The committee deliberated over the matter and asked NARI for clarifications and justifications on the proposal to approve the addition of the arm.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.